Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To determine whether aspirin (ASA) can lower the incidence of Venous Thromboembolism(VTE) in
patients with Glioblastoma (GBM).
Secondary objectives:
To determine clinical and laboratory factors which are associated with increased risk of VTE
If it is determined that ASA reduces the incidence of VTE in patients with GBM, then to
determine the clinical and laboratory factors which are associated with an increased benefit
from the drug.